Alvotech Partners With LOTTE Biologics to Expand US Biosimilar Output
Alvotech and LOTTE Biologics announce a long-term manufacturing deal in Syracuse, NY, aimed at scaling global biosimilar production capacity.
Alvotech (NASDAQ: ALVO) and South Korea-based LOTTE Biologics have announced a long-term manufacturing partnership focused on biosimilar production at a facility in Syracuse, New York, the two companies said on October 6, 2026.
The agreement is part of Reykjavik-based Alvotech's broader strategy to build out its international manufacturing footprint. Alvotech specializes in the development and production of biosimilar medicines for patients worldwide, while LOTTE Biologics focuses on contract biologics manufacturing.
Read more Archer Lewis CEO Jake Nice Earns Crain's 40 Under 40 Honor →
The Syracuse collaboration is designed to increase Alvotech's production capacity for biosimilars, a category of medicines that can expand patient access to complex biological therapies, typically at lower cost than their reference drugs. Adding a U.S.-based manufacturing node aligns with industry and regulatory trends favoring domestic biologics supply chains.
The partnership pairs Alvotech's biosimilar development expertise with LOTTE Biologics' manufacturing capabilities, reflecting a growing pattern of cross-border alliances as drugmakers seek to diversify production and reduce supply-chain risk in the biologics sector.
Continue reading at GlobeNewswire - Industry News on Financial Services.
